Pharmacoeconomic study for cost effectiveness of Genotyping in patients on warfarin therapy with respect to prevention of bleeding episodes - PEPGx

King Edward Memorial Hospital0 个研究点目标入组 280 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients who are to be freshly started on warfarin treatment (naive) for atleast 3 months for various Cardiovascular indications. These are the following indications but not limited to
•a. Patient with valvular heart disease with atrial fibrillation/atrial flutter
•b.Nonvalvular atrial fibrillation with CHADVAS score >1
•c.Patient with deep vein thrombosis, Pulmonary embolism requiring anticoagulation
•d. Dialated Cardiomyopathy with atrial fibrillation
•e. Hypertrophic Cardiomyopathy with atrial fibrillation
•f.Patients with documented thrombus in the left ventricular cavity
•g.Patients having chocked valve who have to undergo mechanical valve prosthesis
•2.Aged 18 years and above of either gender
•3.Patients willing to give voluntarily written informed consent
•4.Patient willing to comply with protocol requirements

•1. Genotype (CYP2C9 and VKORC1) known to participant from prior testing or available in medical record
•2.Pregnancy or lactation
•3.Patients having history of renal and liver insufficiency
•4.Any other clinical condition as per physicianâ??s judgment which compromises safety of the participant or credibility of the data.

发起方